Immuneering Corporation's stock is experiencing a notable increase following the release of promising data from its ongoing Phase 2a trial of IMM-1-104, a therapy for pancreatic cancer. The company reported that the combination of IMM-1-104 with modified gemcitabine/nab-paclitaxel achieved an overall response rate of 43%, significantly surpassing the 23% benchmark from the Phase 3 MPACT study. Additionally, the disease control rate reached 86%, compared to 48% in the MPACT study. These results have generated optimism about the potential of IMM-1-104, with plans for future pivotal clinical trials.
The trial also revealed positive outcomes from the combination of IMM-1-104 with modified FOLFIRINOX, where all evaluable patients experienced tumor shrinkage, including one patient with a 100% reduction. This data, along with the treatment's differentiated tolerability and Fast Track designation from the FDA, has sparked renewed investor interest. Immuneering's plans to expand trials into melanoma and non-small cell lung cancer further contribute to the positive sentiment surrounding the stock.
Immuneering Corporation's stock is currently priced at $1.97, a slight increase from the previous close of $1.96. Despite the early trading hour, the volume remains low at 91,975 shares, representing just 4.60% of the average daily volume of 1,998,347 shares.